Theralase Technologies Inc. (TLT) - Total Assets

Latest as of March 2026: CA$3.89 Million CAD ≈ $2.81 Million USD

Based on the latest financial reports, Theralase Technologies Inc. (TLT) holds total assets worth CA$3.89 Million CAD (≈ $2.81 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Theralase Technologies Inc. to assess the company's total reinvestment commitment from operating cash flow.

Theralase Technologies Inc. - Total Assets Trend (2001–2025)

This chart illustrates how Theralase Technologies Inc.'s total assets have evolved over time, based on quarterly financial data. Check TLT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Theralase Technologies Inc. - Asset Composition Analysis

Current Asset Composition (December 2025)

Theralase Technologies Inc.'s total assets of CA$3.89 Million consist of 58.0% current assets and 42.0% non-current assets.

Asset Category	Amount (CAD)	% of Total Assets
Cash & Equivalents	CA$0.00	5.2%
Accounts Receivable	CA$1.21K	0.0%
Inventory	CA$505.24K	14.5%
Property, Plant & Equipment	CA$0.00	0.0%
Intangible Assets	CA$0.00	0.0%
Goodwill	CA$0.00	0.0%

Asset Composition Trend (2001–2025)

This chart illustrates how Theralase Technologies Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TLT stock market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Theralase Technologies Inc.'s current assets represent 58.0% of total assets in 2025, a decrease from 99.3% in 2001.
Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, down from 99.3% in 2001.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
Asset Diversification: The largest asset category is inventory at 14.5% of total assets.

Theralase Technologies Inc. Competitors by Total Assets

Key competitors of Theralase Technologies Inc. based on total assets are shown below.

Company	Country	Total Assets
SS Innovations International Inc. Common Stock NASDAQ:SSII	USA	$90.55 Million
Medacta Group SA SW:MOVE	Switzerland	CHF860.76 Million
Double Medical Technology Inc SHE:002901	China	CN¥5.03 Billion
Shenzhen New Industries Biomedical SHE:300832	China	CN¥9.58 Billion
Jafron Biomedical Co Ltd SHE:300529	China	CN¥5.52 Billion
Sinocare Inc SHE:300298	China	CN¥6.25 Billion
Xiangyu Medical Co. Ltd. A SHG:688626	China	CN¥3.27 Billion
INKON Life Technology Co Ltd SHE:300143	China	CN¥4.17 Billion

Theralase Technologies Inc. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.37	0.82	8.37
Quick Ratio	1.11	0.52	7.64
Cash Ratio	0.00	0.00	0.00
Working Capital	CA$685.52K	CA$-299.94K	CA$6.31 Million

Theralase Technologies Inc. - Advanced Valuation Insights

This section examines the relationship between Theralase Technologies Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	36.39
Latest Market Cap to Assets Ratio	14.08
Asset Growth Rate (YoY)	7.6%
Total Assets	CA$3.49 Million
Market Capitalization	$49.19 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Theralase Technologies Inc.'s assets at a significant premium (14.08x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: Theralase Technologies Inc.'s assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Theralase Technologies Inc. (2001–2025)

The table below shows the annual total assets of Theralase Technologies Inc. from 2001 to 2025.

Year	Total Assets	Change
2025-12-31	CA$3.49 Million ≈ $2.53 Million	+7.63%
2024-12-31	CA$3.25 Million ≈ $2.35 Million	-0.91%
2023-12-31	CA$3.28 Million ≈ $2.37 Million	-21.25%
2022-12-31	CA$4.16 Million ≈ $3.01 Million	-30.01%
2021-12-31	CA$5.94 Million ≈ $4.30 Million	-40.67%
2020-12-31	CA$10.02 Million ≈ $7.25 Million	-35.22%
2019-12-31	CA$15.47 Million ≈ $11.19 Million	+334.01%
2018-12-31	CA$3.56 Million ≈ $2.58 Million	+7.27%
2017-12-31	CA$3.32 Million ≈ $2.40 Million	-46.76%
2016-12-31	CA$6.24 Million ≈ $4.51 Million	-12.13%
2015-12-31	CA$7.10 Million ≈ $5.14 Million	+86.06%
2014-12-31	CA$3.82 Million ≈ $2.76 Million	+42.17%
2013-12-31	CA$2.68 Million ≈ $1.94 Million	+137.04%
2012-12-31	CA$1.13 Million ≈ $819.34K	-19.72%
2011-12-31	CA$1.41 Million ≈ $1.02 Million	-56.41%
2010-12-31	CA$3.24 Million ≈ $2.34 Million	-22.77%
2009-12-31	CA$4.19 Million ≈ $3.03 Million	+31.72%
2008-12-31	CA$3.18 Million ≈ $2.30 Million	-14.18%
2007-12-31	CA$3.71 Million ≈ $2.68 Million	+0.61%
2006-12-31	CA$3.68 Million ≈ $2.67 Million	+3.81%
2005-12-31	CA$3.55 Million ≈ $2.57 Million	+192.12%
2004-12-31	CA$1.22 Million ≈ $878.97K	+97.59%
2003-12-31	CA$614.96K ≈ $444.85K	+527.06%
2002-12-31	CA$98.07K ≈ $70.94K	-33.10%
2001-12-31	CA$146.59K ≈ $106.04K	--

About Theralase Technologies Inc.

V:TLT Canada Medical Devices

Market Cap

$49.19 Million

CA$68.00 Million CAD

Market Cap Rank

#22007 Global

#780 in Canada

Share Price

CA$0.23

Change (1 day)

-4.17%

52-Week Range

CA$0.15 - CA$0.39

All Time High

CA$0.58